AbbVie's Emblaveo, a groundbreaking aztreonam-avibactam combination, receives FDA approval for treating complicated intra-abdominal infections with limited treatment options.
The European Commission has approved Pfizer's Emblaveo (aztreonam-avibactam), marking the first approval of its class for treating serious multidrug-resistant Gram-negative bacterial infections in adults.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.